Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study

IF 3.2 2区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS ESC Heart Failure Pub Date : 2024-09-28 DOI:10.1002/ehf2.15049

Umut Kocabas, Isil Ergin, Veysel Yavuz, Cihan Altın, Mehmet Kaplan, Gülsüm Meral Yılmaz Öztekin, Mustafa Doğduş, Selda Murat, Bektaş Murat, Tarık Kıvrak, Dilay Karabulut, Ersin Kaya, İbrahim Halil Özdemir, Cennet Yıldız, Fatma Özge Salkın, Emre Özçalık, Şeyda Günay Polatkan, Fahri Çakan, Taner Şen, Umut Karabulut, Sinem Çakal, Ersan Oflar, Ümit Yaşar Sinan, Mustafa Yenerçağ, Uğur Önsel Türk

{"title":"Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study","authors":"Umut Kocabas, Isil Ergin, Veysel Yavuz, Cihan Altın, Mehmet Kaplan, Gülsüm Meral Yılmaz Öztekin, Mustafa Doğduş, Selda Murat, Bektaş Murat, Tarık Kıvrak, Dilay Karabulut, Ersin Kaya, İbrahim Halil Özdemir, Cennet Yıldız, Fatma Özge Salkın, Emre Özçalık, Şeyda Günay Polatkan, Fahri Çakan, Taner Şen, Umut Karabulut, Sinem Çakal, Ersan Oflar, Ümit Yaşar Sinan, Mustafa Yenerçağ, Uğur Önsel Türk","doi":"10.1002/ehf2.15049","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>We aimed to determine the use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19–101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (<i>P</i> = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (<i>P</i> < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06–3.05; <i>P</i> = 0.027], higher household income (OR: 3.46; 95% CI: 1.27–9.42; <i>P</i> = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16–6.35; <i>P</i> = 0.021), diabetes (OR: 9.42; 95% CI: 6.72–13.20; <i>P</i> < 0.001), the use of angiotensin receptor–neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39–7.01; <i>P</i> < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49–2.75; <i>P</i> < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18–2.22; <i>P</i> = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30–2.29; <i>P</i> < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45–0.88; <i>P</i> = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37–0.76; <i>P</i> = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48–0.98; <i>P</i> = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49–0.91; <i>P</i> = 0.010) were independently associated with the non-use of SGLT2is.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The RED–HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.</p>\n </section>\n </div>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":"12 1","pages":"434-446"},"PeriodicalIF":3.2000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769646/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15049","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

We aimed to determine the use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting.

Methods

Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023.

Results

The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19–101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06–3.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27–9.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16–6.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72–13.20; P < 0.001), the use of angiotensin receptor–neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39–7.01; P < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49–2.75; P < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18–2.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30–2.29; P < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45–0.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37–0.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48–0.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49–0.91; P = 0.010) were independently associated with the non-use of SGLT2is.

Conclusions

The RED–HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

心力衰竭患者使用 Empagliflozin 和 Dapagliflozin 的真实世界数据：RED-HEART研究。

目的：我们旨在确定钠-葡萄糖共转运体 2 抑制剂（SGLT2is）的使用情况，并确定在现实生活中心力衰竭（HF）患者使用这些药物的相关临床因素：心力衰竭患者使用 Empagliflozin 和 Dapagliflozin 的真实世界数据：RED-HEART研究是一项多中心、横断面和观察性研究，纳入了2023年8月至2023年12月期间19个心脏病学中心门诊的HF患者，无论其射血分数如何：研究对象包括 1923 名心房颤动患者，以男性为主（61.2%），中位年龄为 66 岁（19-101 岁）。共有 925 名患者（48.1%）正在接受 SGLT2is 治疗。在研究人群中，22.1% 的患者患有射血分数保留型心房颤动，21.5% 的患者患有射血分数轻度降低型心房颤动，56.4% 的患者患有射血分数降低型心房颤动，每组患者使用 SGLT2is 的比例分别为 42.0%、47.9% 和 50.6%（P = 0.012）。心房颤动合并糖尿病患者使用 SGLT2is 的比例为 76.6%，心房颤动合并慢性肾脏病患者为 19.8%，无糖尿病和慢性肾脏病患者为 26.8%（P，结论）：RED-HEART 研究提供了有关心房颤动患者使用 SGLT2is 的全面真实数据。这些结果表明，医疗服务提供者之间需要采取有组织的行动和密切合作，以改善 SGLT2is 的实施，尤其是在射血分数保留的心房颤动和慢性肾病患者中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine

CiteScore

7.00

自引率

7.90%

发文量

461

审稿时长

12 weeks

期刊介绍： ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.